Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Accumulated Expenses (2016 - 2021)

Historic Accumulated Expenses for Fortress Biotech (FBIO) over the last 9 years, with Q3 2021 value amounting to $82.9 million.

  • Fortress Biotech's Accumulated Expenses rose 29208.31% to $82.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $82.9 million, marking a year-over-year increase of 29208.31%. This contributed to the annual value of $45.4 million for FY2020, which is 7870.39% up from last year.
  • According to the latest figures from Q3 2021, Fortress Biotech's Accumulated Expenses is $82.9 million, which was up 29208.31% from $59.9 million recorded in Q2 2021.
  • Fortress Biotech's 5-year Accumulated Expenses high stood at $82.9 million for Q3 2021, and its period low was $1.0 million during Q3 2019.
  • Moreover, its 5-year median value for Accumulated Expenses was $20.4 million (2018), whereas its average is $25.2 million.
  • As far as peak fluctuations go, Fortress Biotech's Accumulated Expenses plummeted by 9489.91% in 2019, and later skyrocketed by 193387.87% in 2020.
  • Fortress Biotech's Accumulated Expenses (Quarter) stood at $17.6 million in 2017, then fell by 7.21% to $16.4 million in 2018, then surged by 55.25% to $25.4 million in 2019, then soared by 78.7% to $45.4 million in 2020, then soared by 82.54% to $82.9 million in 2021.
  • Its Accumulated Expenses was $82.9 million in Q3 2021, compared to $59.9 million in Q2 2021 and $27.8 million in Q1 2021.